X6b912c88.db40.4bde.8333.79829f05fade
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 54
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.410
- FATTY_ACID_METABOLISM+0.370
- MYC_TARGETS_V2+0.330
- MYC_TARGETS_V1+0.300
- XENOBIOTIC_METABOLISM+0.260
- PANCREAS_BETA_CELLS+0.240
- PEROXISOME+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- ADIPOGENESIS+0.200
- BILE_ACID_METABOLISM+0.200
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- NOTCH_SIGNALING-0.490
- TNFA_SIGNALING_VIA_NFKB-0.460
- HEDGEHOG_SIGNALING-0.450
- TGF_BETA_SIGNALING-0.450
- APICAL_SURFACE-0.440
- UV_RESPONSE_DN-0.420
- IL6_JAK_STAT3_SIGNALING-0.390
- APICAL_JUNCTION-0.360
- ANGIOGENESIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20110028.LumB | — | B | 0.879 |
| 2 | 20070010.LumB | — | B | 0.871 |
| 3 | C3L-00415 | — | cohortSQ1 | 0.869 |
| 4 | SRR8392889 | — | cohortMD1 | 0.867 |
| 5 | TCGA-5T-A9QA-01A-11R-A41B-07 | — | B | 0.866 |
| 6 | SRR8518448 | — | C | 0.865 |
| 7 | 4fd42f6e-b04a-4726-b35f-a19d17a6e7bb | — | — | 0.865 |
| 8 | TCGA-BA-A6DL-01A-21R-A30B-07 | — | — | 0.858 |
| 9 | TCGA-CV-A45Z-01A-21R-A24Z-07 | — | — | 0.856 |
| 10 | SRR8518209 | — | C | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |